CD274 and neuroendocrine carcinoma: The findings suggest that immunotherapy, particularly targeting the PD‐1/PD‐L1 pathway, may serve as a promising strategy for the treatment of PNENs, especially for poorly differentiated neuroendocrine carcinomas [23].